Vir Biotechnology, Inc. (VIR)

Over the past six months, Vir Biotechnology's stock price has experienced significant fluctuations, declining by 44.39% from January 13, 2025, to January 9, 2026. The company reported its Q3 2025 earnings on November 5, 2025, and Q2 2025 earnings on August 6, 2025; the stock declined by 5.2% the day after the Q3 2025 earnings announcement. An Annual General Meeting was held on May 29, 2025. On January 13, 2026, shares of Vir Biotechnology were up 7.3% following the release of updated positive Phase 2 SOLSTICE study data for chronic hepatitis delta treatment. In December 2023, the company announced strategic steps to reduce operating expenses, including a 12% workforce reduction and the consolidation of its geographic footprint by closing R&D facilities in St. Louis, Missouri, and Portland, Oregon in 2024.

Significant demand seasonality for Vir Biotechnology's core products and services is not explicitly indicated in the available information, given its focus on chronic infectious diseases and oncology. While the company has had pipeline candidates for seasonal infectious diseases such as influenza A, there is no clear evidence of overall product or service demand seasonality for Vir Biotechnology's current portfolio.

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on discovering and developing medicines for serious infectious diseases and cancer, operating within the Biotechnology, Drug Discovery, Pharmaceuticals, and Healthcare sectors. The company leverages the immune system through its technology platforms: antibodies, T cells, innate immunity, and siRNA. Its pipeline includes product candidates targeting conditions such as hepatitis B, hepatitis delta, influenza A, HIV, tuberculosis, and various solid tumors, and has also worked on treatments for COVID-19 and Ebola. Revenue sources include collaboration, contract, grant, and license revenue.

Vir Biotechnology is headquartered in San Francisco, California, and conducts operations and R&D in the U.S. and Switzerland, specifically in San Francisco and Bellinzona. In 2024, the company closed its R&D facilities in St. Louis, Missouri, and Portland, Oregon, as part of a strategic restructuring.

Vir Biotechnology's brand reputation has been influenced by positive clinical advancements and strategic corporate adjustments. The company was recognized on Inc.'s 250 Best-Led U.S. Companies list in 2021, and positive Phase 2 SOLSTICE study data for chronic hepatitis delta treatment, announced in January 2026, is a significant positive event. A strategic partnership with Norgine to expand access to hepatitis delta treatment across Europe, Australia, and New Zealand also contributes positively to its image. However, a restructuring plan involving a 12% workforce reduction and the closure of some R&D facilities in 2024, following the failure of an experimental influenza candidate in a clinical trial earlier in 2023, coupled with the stock's underperformance and ongoing financial struggles, may have negatively impacted stakeholder confidence.

Vir Biotechnology, Inc. has a diverse ownership structure, including institutional investors, insiders, and the general public. As of September 2025, institutional owners held approximately 77.0% of the company's shares. Major institutional shareholders include SB Investment Advisers (UK) Ltd, BlackRock, Inc., Arch Venture Corp, Vanguard Group Inc, State Street Corp, Fmr Llc, Dimensional Fund Advisors Lp, Morgan Stanley, Orbimed Advisors LLC, and Geode Capital Management, LLC. Insiders also hold a noticeable percentage of the company's shares.